16075278

Source:http://linkedlifedata.com/resource/pubmed/id/16075278

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0006141, umls-concept:C0008838, umls-concept:C0009368, umls-concept:C0069717, umls-concept:C0086418, umls-concept:C0205195, umls-concept:C0334227, umls-concept:C0532362, umls-concept:C0596402, umls-concept:C1140680, umls-concept:C1880022
pubmed:issue	4
pubmed:dateCreated	2006-1-11
pubmed:abstractText	This study assessed the cytotoxic effects of irofulven in combination with oxaliplatin and cisplatin in a panel of human cancer cell lines.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7806519
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Alkylating, http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin, http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds, http://linkedlifedata.com/resource/pubmed/chemical/Sesquiterpenes, http://linkedlifedata.com/resource/pubmed/chemical/Tetrazolium Salts, http://linkedlifedata.com/resource/pubmed/chemical/Thiazoles, http://linkedlifedata.com/resource/pubmed/chemical/irofulven, http://linkedlifedata.com/resource/pubmed/chemical/oxaliplatin, http://linkedlifedata.com/resource/pubmed/chemical/thiazolyl blue
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	0344-5704
pubmed:author	pubmed-author:CalvoFabienF, pubmed-author:CvitkovicEstebanE, pubmed-author:KoeppelFlorenceF, pubmed-author:LaarEmily S VanES, pubmed-author:LarsenAnnette KAK, pubmed-author:LokiecFrançoisF, pubmed-author:PoindessousVirginieV, pubmed-author:RaymondEricE, pubmed-author:SerovaMariaM, pubmed-author:WatersStephen JSJ
pubmed:issnType	Print
pubmed:volume	57
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	491-9
pubmed:meshHeading	pubmed-meshheading:16075278-Algorithms, pubmed-meshheading:16075278-Antineoplastic Agents, pubmed-meshheading:16075278-Antineoplastic Agents, Alkylating, pubmed-meshheading:16075278-Apoptosis, pubmed-meshheading:16075278-Breast Neoplasms, pubmed-meshheading:16075278-Cell Cycle, pubmed-meshheading:16075278-Cell Line, Tumor, pubmed-meshheading:16075278-Cell Proliferation, pubmed-meshheading:16075278-Cisplatin, pubmed-meshheading:16075278-Colonic Neoplasms, pubmed-meshheading:16075278-Drug Resistance, Multiple, pubmed-meshheading:16075278-Drug Resistance, Neoplasm, pubmed-meshheading:16075278-Drug Synergism, pubmed-meshheading:16075278-Female, pubmed-meshheading:16075278-Genes, p53, pubmed-meshheading:16075278-HT29 Cells, pubmed-meshheading:16075278-Humans, pubmed-meshheading:16075278-Organoplatinum Compounds, pubmed-meshheading:16075278-Ovarian Neoplasms, pubmed-meshheading:16075278-Sesquiterpenes, pubmed-meshheading:16075278-Tetrazolium Salts, pubmed-meshheading:16075278-Thiazoles
pubmed:year	2006
pubmed:articleTitle	Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
pubmed:affiliation	EMI0334, Hôpital Saint-Louis, Paris, France.
pubmed:publicationType	Journal Article